Quantitative Concept – Page 11

Third Harmonic Bio to Liquidate, Selling Key Urticaria Drug Asset THB335

3 months ago talkbio0Tagged biopharma exit strategy, Chronic Spontaneous Urticaria, clinical-stage, CSU, drug sales, Inhibitor, KIT, Kit device, shareholder, THB335, Third Harmonic Bio liquidation, value maximization

Third Harmonic Bio liquidation , THB335 drug sale , chronic spontaneous urticaria (CSU) , KIT inhibitor , biopharma exit strategy , clinical-stage biotech , shareholder value maximization

PRISM BioLab and Elix Collaborate to Revolutionize AI-Driven Drug Discovery with Peptide Mimetics

3 months ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, Drug Discovery, Efficiency, Elix, mimetics, PepMetics, Peptides, pharmaceutical innovation, PRISM BioLab, Protein-Protein Interaction, small molecule inhibitors

PRISM BioLab , Elix , AI drug discovery , Peptide mimetics , Protein-protein interactions , PepMetics® , Small molecule inhibitors , Drug discovery efficiency , Pharmaceutical innovation

FDA Union Prepares for Negotiations as HHS Job Cuts Reshape Workforce

3 months ago talkbio0Tagged Advocacy, CHARGE Syndrome, employee layoffs, federal, Force, layoffs, Mediation, public health medicine (field), reduction in force, restructuring, Union, United States Food and Drug Administration

FDA layoffs, HHS restructuring, Union negotiations, Reduction in Force (RIF), Robert F. Kennedy Jr., FDA workforce reduction, HHS employee layoffs, Federal health agencies, Public health impact, Union advocacy

Amgen Secures Phase 3 Survival Data for Imdelltra in Small-Cell Lung Cancer, Strengthening Its Case for Full FDA Approval

3 months ago talkbio0Tagged amgen, Biological Factors, DLL3-targeting therapy, Imdelltra, Immunotherapy, Overall Survival, Phase 3 trial, SCLC, small-cell lung cancer

Imdelltra, Amgen, Small-cell lung cancer (SCLC), Phase 3 trial, Overall survival, DLL3-targeting therapy, Immunotherapy, Biopharmaceuticals

Verve’s 2nd swing at PCSK9 editing yields clean safety profile, teeing up Lilly opt-in decision

3 months ago talkbio0Tagged Safety, VERVE-102

VERVE-102, Safety

As Pfizer backs out of hemophilia gene therapy space, CSL hopes Hemgenix is here to stay

4 months ago talkbio0Tagged alternatives, Clinical Trials, gene therapy, Hemgenix, HYMPAVZI, Pfizer, SMPX gene

Hemgenix, SMPX gene, Pfizer, gene therapy, alternatives, HYMPAVZI, Clinical Trials

Navigating Challenges: Keros and Tempest Aim to Stabilize and Strategize for Growth

4 months ago talkbio0Tagged biopharmaceutical sector, Biotechnology, Clinical Trials, Corporate, financial, Infantile Neuroaxonal Dystrophy, Investments, restructuring, stockholder, strategic alternatives

Keros Therapeutics , Strategic alternatives , Financial challenges , Biopharmaceutical sector , Stockholder rights plan , Clinical trials , Tempest Therapeutics , Corporate restructuring , Biotechnology investments

Pharma stocks swerve as Trump hits pause on most tariffs

4 months ago talkbio0Tagged Market, Pauses, Transplant Registry Unified Management Program

Market, Transplant Registry Unified Management Program, Pauses

Drug pricing watchdog ICER offers ways to increase obesity drug access

4 months ago talkbio0Tagged Access, drug price, ICER, Obesity, Policy, Wegovy

ICER, Obesity, Access, Wegovy, Policy, drug price

Trump Announces Imminent Major Tariffs on Pharmaceuticals: Implications for Global Markets and U.S. Manufacturing

4 months ago talkbio0Tagged drug price, Impact food supplement, Pharma import taxes, pharmaceutical manufacturing, Pharmaceutical stocks, pharmaceutical tariffs, Policy, Relations, TNFRSF19 gene, Transplant Registry Unified Management Program, U.S.-China, United States

Trump pharmaceutical tariffs, U.S. pharmaceutical manufacturing, Pharma import taxes, Drug price impact, Trade policy 2025, U.S.-China trade relations, Pharmaceutical stocks